NasdaqGM · Biotechnology

Connect Biopharma (CNTB)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+207.2%

$7.25 average target

$2.36+0.08 (+3.5%)Latest market snapshot · Yahoo Finance

Market cap$148.6M

Cash$31.5M

Quarterly burn$16.0M

Pipeline assets10

Short float4.6%

Latest coverage

News & Press Releases

External sources

Aug 12, 2026

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire

Jul 9, 2026

Oppenheimer Initiates Connect Biopharma at Outperform With $8 Price TargetMT Newswires

Jun 17, 2026

Connect Biopharma Completes Enrollment in Phase 2 Rademikibart Asthma StudyMT Newswires

Continue with BioPharma ProUnlock 2 more recent stories and press releases.

Unlock Pro

Company profile

About Connect Biopharma

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.